The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) will meet from 4 to 7 May 2026 to discuss safety signals and regulatory actions for several medicines, according to the agenda published on 5 May 2026. The meeting will impact pharmaceutical companies, healthcare professionals, and patients across the EU, as any recommendations could lead to changes in product information or restrictions on use.
The agenda, released by EMA's Pharmacovigilance and Epidemiology Department, outlines the topics for discussion. As a committee agenda, it is a planning document that sets the stage for mandatory evaluations; PRAC's final recommendations will be published after the meeting. The document does not include specific numerical targets but signals the committee's intention to review ongoing safety concerns.
Key items include a review of GLP-1 receptor agonists for potential thyroid cancer risk, an update on the safety of JAK inhibitors in inflammatory conditions, and an assessment of mRNA vaccine safety data for seasonal updates. These reviews reflect a trade-off between ensuring patient safety and maintaining access to effective therapies. For pharmaceutical companies, any new restrictions could affect market authorizations and prescribing patterns. Healthcare professionals may face updated guidance, while patients could see changes in treatment options or monitoring requirements.
The meeting also covers signal detection procedures and post-authorization studies for several drugs. PRAC's discussions are expected to lead to recommendations that will be forwarded to EMA's Committee for Medicinal Products for Human Use (CHMP) for final decision. The outcomes are likely to be published in the coming weeks, with potential regulatory actions including updates to product labels or suspension of marketing authorizations.
← Atlas › News › Health & Lifestyle